BG
RYTM icon

Bellevue Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bellevue Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.4K Sell
1,016
-6,488
-86% -$631K ﹤0.01% 141
2025
Q4 		$803K Sell
7,504
-1,549
-17% -$164K 0.02% 116
2025
Q3 		$914K Sell
9,053
-11,853
-57% -$1.1M 0.02% 108
2025
Q2 		$1.32M Buy
20,906
+5,356
+34% +$328K 0.03% 102
2025
Q1 		$824K Sell
15,550
-8,046
-34% -$446K 0.02% 110
2024
Q4 		$1.32M Buy
23,596
+7,896
+50% +$436K 0.03% 113
2024
Q3 		$823K Buy
15,700
+2,700
+21% +$129K 0.01% 123
2024
Q2 		$534K Buy
13,000
+500
+4% +$20K 0.01% 127
2024
Q1 		$542K Sell
12,500
-20,369
-62% -$891K 0.01% 128
2023
Q4 		$1.51M Sell
32,869
-40,431
-55% -$1.28M 0.02% 114
2023
Q3 		$1.68M Buy
+73,300
New +$1.64M 0.03% 115

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bellevue Group's RYTM Position: Q1 2026 in Review

Bellevue Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 86% in Q1 2026, selling an estimated $631K and leaving 1,016 shares worth $88.4K. The position accounts for ﹤0.01% of the portfolio, ranked #141.

Bellevue Group first reported a position in RYTM in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.68M in Q3 2023. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Bellevue Group held 1,016 shares of Rhythm Pharmaceuticals worth $88.4K as of Q1 2026.
  • Bellevue Group sold 6,488 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $631K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Bellevue Group's portfolio in Q1 2026, its #141 holding.
  • Bellevue Group first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Bellevue Group's Rhythm Pharmaceuticals position peaked at $1.68M in Q3 2023.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.